Bullseye | AC8 - AusCann Group Holdings Ltd

Company Overview

Develop a portfolio of cannabinoid-based medicines that expands the therapeutic applications of cannabis, offering both people and pets benefit for the treatment of inadequately met medical needs.

Website	www.auscann.com.au
Head Office	West Perth WA
Registry	Computershare Investor Services
CEO	Layton Mills
Chair Person	Tod McGrouther
GICS Industry	Pharmaceuticals, Biotechnology & Life Sciences
Sub Industry	Pharmaceuticals
Sector	Health Care

Market Cap	$18 m
Shares on Issue	440 m
Status	Suspended
Last Price
Change
52 Week H/L
VWAP
Bid/Ask

Directors and Management

Ms Krista Bates

Non-Executive Director 20/12/2019

Ms Bates brings over 18 years of experience in the legal market. She is currently a Partner at Lavan and is Head of Mining & Resources. Krista has led transactions across multiple sectors advising a base of private and listed companies, private equity funds, governments and individuals, nationally and internationally.

BA(Hons), GradDip(Law), PostGradDip(Law),GAICD Female

Mr Geoff Starr

Non-Executive Director 01/04/2021

Male

Mr Robert Clifford

Non-Executive Director 01/04/2021

Male

Dr Kathryn (Kate) Claire Adams

Non-Executive Director 01/04/2021

Mst(data Analy. pursuing) Female

Mr Bruce Fielding McHarrie

Non-Executive Director 19/01/2017

Mr McHarrie is experienced senior executive and independent company director with a background in the life sciences industry in finance, operations, governance, business and investment management, and strategic planning. He previously served as the Chief Financial Officer, Director of Operations and Director of Strategic Projects with the Telethon Kids Institute in Western Australia. Prior to joining the Institute, Bruce was based in London as an Assistant Director at Rothschild Asset Management in the Bioscience Unit. He co-founded Phylogica Limited and has held a number of other non- executive director positions in biotechnology and not-for-profit healthcare organisations.

BCom, FCA, GAICD Chartered Accountant Male

Mr Christopher (Chris) Lee Mews

Non-Executive Director 01/12/2019

Mr Mews is an experienced non-executive director with over 20 years in the financial services sector, having held senior positions in finance, corporate secretarial and compliance in listed and unlisted companies. Chris is currently the Chief Financial Officer and Company Secretary of Merchant Group Pty Ltd.

BBus(Acc),CPA,CCS,MGIA,GAICD Chartered Company Secretary Male

Mr Robert (Max) Maxwell Johnston

Non-Executive Director,Non-Executive Chairman 20/12/2019

Mr Johnston is a health care industry director with a range of executive and pharmaceutical experience. He previously held the position of President and Chief Executive Officer of Johnson & Johnson Pacific for 11 years.

FCDA, MAICD Male

Top 20 Shareholders

	Name	Shares	%
1.	The Trust Company (Australia) Limited <M0F> A/C	39,000,000	12.30
2.	Citicorp Nominees Pty Limited	11,714,708	3.38
3.	Ms Elaine Lucy Darby	6,816,838	2.15
4.	Merrill Lynch (Austraua) Nominees Pty Umited	5,875,409	1.85
5.	Mal Washer Nominees Ft( Ltd	5,300,632	1.67
6.	J P Morgan Nominees Austraua Limited	4,463,186	1.41
7.	Mr Warren Sidney Langman	4,235,928	1.34
8.	HSBC Custody Nominees (Australia) Limited	2,999,292	0.95
9.	BNP Paribas Nominees Pty Ltd < Ib Au Noms Retail Went Drp>	2,805,532	0.88
10.	Celtic Capital Pty Ltd <Celtic Capital A/C>	2,348,106	0.73
11.	Wil & Jack Ft( Ltd <Wil & Jack Family A/C>	2,348,106	0.74
12.	Mr George Chien Hsun Lu & Mrs Jenny Chin Pao Lu	2,195,000	0.69
13.	Danny Stephens Investments Pty Ltd <Danny Stephens Family A/C>	2,150,200	0.68
14.	Mr Anthony Nicholas Nagy	2,061,846	0.65
15.	Bnp Paribas Noms Pty Ltd < Drp>	1,941,237	0.61
16.	Pershing Australia Nominees Pty Ltd <Accum A/C>	1,726,435	0.54
17.	Noldex Pty Ltd	1,573,918	0.50
18.	Mr George Chien Hsun Lu	1,390,000	0.44
19.	HSBC Custody Nominees (Australia) Limited (I)	1,257,407	0.40
20.	Alava Holdings Limited	1,250,000	0.39

Director Transactions

Date	Name	Qty	Value	Direction	Notes
14/05/2021	Geoff Starr	100,000	$11,500	Buy	On-market trade.
15/04/2021	Robert (Max) Johnston	110,000	$15,400	Buy	On-market trade.
18/03/2021	Krista Bates	292,500	$42,412	Buy	As advised by the company. Shares acquired under the Scheme of Arrangement with CannPal Animal Therapeutics Ltd.
18/03/2021	Christopher (Chris) Mews	279,689	$40,554	Buy	As advised by the company. Shares acquired under the Scheme of Arrangement with CannPal Animal Therapeutics Ltd (ASX:CP1) under which CP1 shareholders received 1.3 new AC8 shares for every 1 CP1 share held at the record date.
18/03/2021	Robert (Max) Johnston	390,000	$56,550	Buy	As advised by the company. Shares acquired under the Scheme of Arrangement with CannPal Animal Therapeutics Ltd.